Fig. 2: FasL AM MPBCs treatment does not affect the expansion capacity of CD34+ cells. | Bone Marrow Transplantation

Fig. 2: FasL AM MPBCs treatment does not affect the expansion capacity of CD34+ cells.

From: Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

Fig. 2

Characterization of HSPCs purified from 100 ng/ml FasL AM treated (a–h) or 400 ng/ml FasL AM treated (i–p) MPBCs and from control MPBCs followed by 7 days expansion. Total cell number per well, (b, j) percent of CD34+ cells per total cells in culture. Percentage of HSPCs subpopulations per total CD34+ population: (c, k) self-renewal HSCs (CD34+CD38neg/low CD90+CD45RA−), (d, l) MPPs (CD34+CD38neg/low CD90−CD45RA−), (e, m) LMPPs (CD38Neg/LowCD90−CD45RA+), (f, n) OPPs (CD38+high) (g, o) early-stage MkPs (h, p) and more mature MkPs (CD38neg/lowCD41a+ and CD38highCD41a+, respectively). N = 3, Mean ± SEM, *P ≤ 0.05 Paired T-test.

Back to article page